



This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently amended) A compound, comprising: a targeting moiety and a chelator, wherein the targeting moiety is bound to the chelator, is a indazole nonpeptide, and binds to a receptor that is upregulated during angiogenesis and the compound has 0-1 linking groups between the targeting moiety and chelator
wherein the indazole nonpeptide targeting moiety is represented by (Q)_d wherein Q is independently a a compound of Formula (Ia) or (Ib):



(Ia)



(Ib)

or pharmaceutically acceptable salt form thereof wherein:

DOCKET NO.: DM-6999 (BMS-2594)
Application No.: 10/770,380
Office Action Dated: June 16, 2006

PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116

X^{1d} is CH, C- W^d- X^d- Y^d, or C bonded to the linking group;

X^{2d} is CH, or C- W^d- X^d- Y^d;










X^{3d} is CR^{11d}, or C- W^d- X^d- Y^d;

X^{4d} is CR^{11d};


provided that when R^{1d} is R^{1de} then one of X^{1d} and X^{2d} is C- W^d- X^d- Y^d, and when R^{10d} is R^{1de} then X^{3d} is C- W^d- X^d- Y^d;

R^{1d} is R^{1de}, C₁-C₆ alkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C₃-C₆ alkenyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C₃-C₇ cycloalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C₄-C₁₁ cycloalkylalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, aryl substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d}, or aryl(C₁-C₆ alkyl)- substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d};

R^{1d} is



or



A^d and B^d are independently -CH₂-, -O-, -N(R^{2d})-, or -C(=O)-;

A^{1d} and B^{1d} are independently -CH₂- or -N(R^{3d})-;

D^d is -N(R^{2d})-, -O-, -S-, -C(=O)- or -SO₂-;

E^d-F^d is -C(R^{4d})=C(R^{5d})-, -N=C(R^{4d})-, -C(R^{4d})=N-, or
-C(R^{4d})₂C(R^{5d})₂-;

J^d, K^d, L^d and M^d are independently
-C(R^{4d})-, -C(R^{5d})- or -N-, provided that at least one of J^d, K^d, L^d and M^d is not -N-;

R^{2d} is H, C₁-C₆ alkyl, (C₁-C₆ alkyl)carbonyl, (C₁-C₆ alkoxy)carbonyl; (C₁-C₆
alkyl)aminocarbonyl, C₃-C₆ alkenyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl,
aryl, heteroaryl(C₁-C₆ alkyl)carbonyl, heteroarylcarbonyl,
aryl(C₁-C₆ alkyl)-, (C₁-C₆ alkyl)carbonyl-, arylcarbonyl, C₁-C₆ alkylsulfonyl,
arylsulfonyl, aryl(C₁-C₆ alkyl)sulfonyl, heteroarylsulfonyl, heteroaryl(C₁-C₆
alkyl)sulfonyl, aryloxy carbonyl, or aryl(C₁-C₆ alkoxy)carbonyl, wherein said aryl
groups are substituted with 0-2 substituents selected from the group consisting of C₁-
C₄ alkyl, C₁-C₄ alkoxy, halo, CF₃, and nitro;

R^{3d} is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-,
or heteroaryl(C₁-C₆ alkyl)-;

R^{4d} and R^{5d} are independently H, C₁-C₄ alkoxy, NR^{2d}R^{3d}, halogen, NO₂, CN, CF₃, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-, (C₁-C₆ alkyl)carbonyl, (C₁-C₆ alkoxy)carbonyl, or arylcarbonyl, or

alternatively, when substituents on adjacent atoms, R^{4d} and R^{5d} can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, halo, cyano, amino, CF₃, and NO₂;

U^d is:

-(CH₂)_{n^d}-

-(CH₂)_{n^d}(CR^{7d}=CR^{8d})(CH₂)_{m^d}-

-(CH₂)_{n^d}(C≡C)(CH₂)_{m^d}-

-(CH₂)_{t^d}Q^d(CH₂)_{m^d}-

-(CH₂)_{n^d}O(CH₂)_{m^d}-

-(CH₂)_{n^d}N(R^{6d})(CH₂)_{m^d}-

-(CH₂)_{n^d}C(=O)(CH₂)_{m^d}-

-(CH₂)_{n^d}(C=O)N(R^{6d})(CH₂)_{m^d}-

-(CH₂)_{n^d}N(R^{6d})(C=O)(CH₂)_{m^d}-, and

-(CH₂)_{n^d}S(O)_{p^d}(CH₂)_{m^d}-;

wherein one or more of the methylene groups in U^d is optionally substituted with R^{7d};

Q^d is 1,2-cycloalkylene, 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, 2,3-pyridinylene, 3,4-pyridinylene, 2,4-pyridinylene, or 3,4-pyridazinylene;

R^{6d} is H, C₁-C₄ alkyl, or benzyl;

R^{7d} and R^{8d} are independently H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-, or heteroaryl(C₀-C₆ alkyl)-;

R^{10d} is H, R^{1de}, C₁-C₄ alkoxy substituted with 0-1 R^{21d}, N(R^{6d})₂, halogen, NO₂, CN, CF₃, CO₂R^{17d}, C(=O)R^{17d}, CONR^{17d}R^{20d}, -SO₂R^{17d}, -SO₂NR^{17d}R^{20d}, C₁-C₆ alkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C₃-C₆ alkenyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C₃-C₇ cycloalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C₄-C₁₁ cycloalkylalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, aryl substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d}, or aryl(C₁-C₆ alkyl)- substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d};

R^{10de} is H, C₁-C₄ alkoxy substituted with 0-1 R^{21d}, N(R^{6d})₂, halogen, NO₂, CN, CF₃, CO₂R^{17d}, C(=O)R^{17d}, CONR^{17d}R^{20d}, -SO₂R^{17d}, -SO₂NR^{17d}R^{20d}, C₁-C₆ alkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C₃-C₆ alkenyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C₃-C₇ cycloalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C₄-C₁₁ cycloalkylalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, aryl substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d}, or aryl(C₁-C₆ alkyl)- substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d};

R^{11d} is H, halogen, CF₃, CN, NO₂, hydroxy, NR^{2d}R^{3d}, C₁-C₄ alkyl substituted with 0-1 R^{21d}, C₁-C₄ alkoxy substituted with 0-1 R^{21d}, aryl substituted with 0-1 R^{21d}, aryl(C₁-C₆ alkyl)- substituted with 0-1 R^{21d}, (C₁-C₄ alkoxy)carbonyl substituted with 0-1 R^{21d}, (C₁-C₄ alkyl)carbonyl substituted with 0-1 R^{21d};

C₁-C₄ alkylsulfonyl substituted with 0-1 R^{21d}, or C₁-C₄ alkylaminosulfonyl substituted with 0-1 R^{21d}.


W^d is:

-(C(R^{12d})₂)_q^dC(=O)N(R^{13d})-, or

-C(=O)-N(R^{13d})-(C(R^{12d})₂)_q^d-;

X^d is -C(R^{12d})(R^{14d})-C(R^{12d})(R^{15d})-; or

alternatively, W^d and X^d can be taken together to be



R^{12d} is H, halogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, (C₁-C₄ alkyl)carbonyl, aryl, or aryl(C₁-C₆ alkyl)-;

R^{13d} is H, C₁-C₆ alkyl, C₃-C₇ cycloalkylmethyl, or aryl(C₁-C₆ alkyl)-;

R^{14d} is:


H, C₁-C₆ alkylthio(C₁-C₆ alkyl)-, aryl(C₁-C₁₀ alkylthioalkyl)-, aryl(C₁-C₁₀ alkoxyalkyl)-, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxyalkyl, C₁-C₆ hydroxyalkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cycloalkylalkyl, aryl(C₁-C₆ alkyl)-, heteroaryl(C₁-C₆ alkyl)-, aryl, heteroaryl, CO₂R^{17d}, C(=O)R^{17d}, or CONR^{17d}R^{20d}, provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 1 R^{16d} or 1-2 R^{11d}.

R^{15d} is:

H, R^{16d}, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxyalkyl, C₁-C₁₀ alkylaminoalkyl, C₁-C₁₀ dialkylaminoalkyl, (C₁-C₁₀ alkyl)carbonyl, aryl(C₁-C₆ alkyl)carbonyl, C₁-C₁₀ alkenyl, C₁-C₁₀ alkynyl, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cycloalkylalkyl, aryl(C₁-C₆ alkyl)-, heteroaryl(C₁-C₆ alkyl)-, aryl, heteroaryl, CO₂R^{17d}, C(=O)R^{17d}, CONR^{17d}R^{20d}, SO₂R^{17d}, or SO₂NR^{17d}R^{20d}, provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 1-2 R^{11d}.

Y^d is:

-COR^{19d}, -SO₃H, -PO₃H, tetrazolyl, -CONHNHSO₂CF₃, -CONHSO₂R^{17d}, -CONHSO₂NHR^{17d}, -NHCOCF₃, -NHCONHSO₂R^{17d}, -NHSO₂R^{17d}, -OPO₃H₂, -OSO₃H, -PO₃H₂, -SO₃H, -SO₂NHCOR^{17d}, -SO₂NHCO₂R^{17d},



R^{16d} is:

-N(R^{20d})-C(=O)-O-R^{17d},
-N(R^{20d})-C(=O)-R^{17d},
-N(R^{20d})-C(=O)-NH-R^{17d},
-N(R^{20d})SO₂-R^{17d}, or
-N(R^{20d})SO₂-NR^{20d}R^{17d}.

R^{17d} is:

C₁-C₁₀ alkyl optionally substituted with a bond to the linking group, C₃-C₁₁ cycloalkyl optionally substituted with a bond to the linking group, aryl(C₁-C₆ alkyl)- optionally substituted with a bond to the linking group, (C₁-C₆ alkyl)aryl optionally substituted with a bond to the linking group, heteroaryl(C₁-C₆ alkyl)- optionally substituted with a bond to the linking group, (C₁-C₆ alkyl)heteroaryl optionally substituted with a bond to the linking group, biaryl(C₁-C₆ alkyl)- optionally substituted with a bond to the linking group, heteroaryl optionally substituted with a bond to the linking group, aryl optionally substituted with a bond to the linking group, biaryl optionally substituted with a bond to the linking group, or a bond to the linking group, wherein said aryl, biaryl or heteroaryl groups are also optionally substituted with 0-3 substituents selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, aryl, heteroaryl, halo, cyano, amino, CF₃, and NO₂;

R^{18d} is:

-H,
-C(=O)-O-R^{17d},
-C(=O)-R^{17d},
-C(=O)-NH-R^{17d},
-SO₂-R^{17d}, or
-SO₂-NR^{20d}R^{17d}.

R^{19d} is hydroxy, C₁-C₁₀ alkyloxy, C₃-C₁₁ cycloalkyloxy, aryloxy, aryl(C₁-C₆ alkoxy)-, C₃-C₁₀ alkylcarbonyloxyalkyloxy, C₃-C₁₀ alkoxy carbonyloxyalkyloxy, C₂-C₁₀ alkoxy carbonylalkyloxy, C₅-C₁₀ cycloalkylcarbonyloxyalkyloxy, C₅-C₁₀ cycloalkoxy carbonyloxyalkyloxy, C₅-C₁₀ cycloalkoxy carbonylalkyloxy, C₇-C₁₁ aryloxy carbonylalkyloxy, C₈-C₁₂ aryloxy carbonyloxyalkyloxy,

C₈-C₁₂ arylcarbonyloxyalkyloxy, C₅-C₁₀ alkoxyalkylcarbonyloxyalkyloxy,
C₅-C₁₀ (5-alkyl-1,3-dioxo-cyclopenten-2-one-yl)methyloxy, C₁₀-C₁₄ (5-aryl-1,3-
dioxo-cyclopenten-2-one-yl)methyloxy, or (R^{11d})(R^{12d})N-(C₁-C₁₀ alkoxy)-;

R^{20d} is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-,
or heteroaryl(C₁-C₆ alkyl)-;

R^{21d} is COOH or NR^{6d}₂;

m^d is 0-4;

n^d is 0-4;

t^d is 0-4;

p^d is 0-2;

q^d is 0-2;

r^d is 0-2; and

d is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;


with the following provisos:

(1) t^d, n^d, m^d and q^d are chosen such that the number of atoms connecting R^{1d} and Y^d is in
the range of 10-14; and


(2) n^d and m^d are chosen such that the value of n^d plus m^d is greater than one unless U^d is
-(CH₂)_t^d Q^d (CH₂)_m^d-.

2-57. Canceled.


58. (New) A compound according to Claim 1, wherein the receptor is the integrin $\alpha_v\beta_3$ or $\alpha_v\beta_5$ and the compound is of the formula:



wherein, Q is independently a compound of Formula (Ia) or (Ib):



(Ia)



(Ib)

or pharmaceutically acceptable salt form thereof wherein:

X^{1d} is CH , $C-W^d$, X^d , Y^d , or C bonded to L_n ;

DOCKET NO.: DM-6999 (BMS-2594)
Application No.: 10/770,380
Office Action Dated: June 16, 2006

PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116

X^{2d} is CH₃, or C-W^d-X^d-Y^d;

X^{3d} is CR^{11d}, or C-W^d-X^d-Y^d;






X^{4d} is CR^{11d};

provided that when R^{1d} is R^{1de} then one of X^{1d} and X^{2d} is C-W^d-X^d-Y^d, and when R^{10d} is R^{1de} then X^{3d} is C-W^d-X^d-Y^d;

R^{1d} is R^{1de}, C₁-C₆ alkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C₃-C₆ alkenyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C₃-C₇ cycloalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C₄-C₁₁ cycloalkylalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, aryl substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d}, or aryl(C₁-C₆ alkyl)- substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d};

R^{1de} is

**PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116**



A^d and B^d are independently -CH₂-, -O-, -N(R^{2d})-, or -C(=O)-;

A^{1d} and B^{1d} are independently -CH₂- or -N(R^{3d})-;

D^d is -N(R^{2d})-, -O-, -S-, -C(=O)- or -SO₂-;

E^d-F^d is -C(R^{4d})=C(R^{5d})-, -N=C(R^{4d})-, -C(R^{4d})=N-, or
-C(R^{4d})₂C(R^{5d})₂-;

J^d, K^d, L^d and M^d are independently
-C(R^{4d})-, -C(R^{5d})- or -N-, provided that at least one of J^d, K^d, L^d and M^d is not -N-;

R^{2d} is H, C₁-C₆ alkyl, (C₁-C₆ alkyl)carbonyl, (C₁-C₆ alkoxy)carbonyl; (C₁-C₆ alkyl)aminocarbonyl, C₃-C₆ alkenyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, heteroaryl(C₁-C₆ alkyl)carbonyl, heteroarylcarbonyl, aryl(C₁-C₆ alkyl)-, (C₁-C₆ alkyl)carbonyl-, arylcarbonyl, C₁-C₆ alkylsulfonyl, arylsulfonyl, aryl(C₁-C₆ alkyl)sulfonyl, heteroarylsulfonyl, heteroaryl(C₁-C₆ alkyl)sulfonyl, aryloxycarbonyl, or aryl(C₁-C₆ alkoxy)carbonyl, wherein said aryl groups are substituted with 0-2 substituents selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, halo, CF₃, and nitro;

R^{3d} is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-, or heteroaryl(C₁-C₆ alkyl)-;

R^{4d} and R^{5d} are independently H, C₁-C₄ alkoxy, $NR^{2d}R^{3d}$, halogen, NO₂, CN, CF₃, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-, (C₁-C₆ alkyl)carbonyl, (C₁-C₆ alkoxy)carbonyl, or arylcarbonyl, or

alternatively, when substituents on adjacent atoms, R^{4d} and R^{5d} can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, halo, cyano, amino, CF₃, and NO₂;

U^d is:

$-(CH_2)_n^d-$,
 $-(CH_2)_n^d(CR^{7d}=CR^{8d})(CH_2)_m^d-$,
 $-(CH_2)_n^d(C\equiv C)(CH_2)_m^d-$,
 $-(CH_2)_t^dQ^d(CH_2)_m^d-$,
 $-(CH_2)_n^dO(CH_2)_m^d-$,
 $-(CH_2)_n^dN(R^{6d})(CH_2)_m^d-$,
 $-(CH_2)_n^dC(=O)(CH_2)_m^d-$,
 $-(CH_2)_n^d(C=O)N(R^{6d})(CH_2)_m^d-$
 $-(CH_2)_n^dN(R^{6d})(C=O)(CH_2)_m^d-$, and
 $-(CH_2)_n^dS(O)_p^d(CH_2)_m^d-$;

wherein one or more of the methylene groups in U^d is optionally substituted with R^{7d} ;

Q^d is 1,2-cycloalkylene, 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, 2,3-pyridinylenes, 3,4-pyridinylenes, 2,4-pyridinylenes, or 3,4-pyridazinylenes;

R^{6d} is H, C₁-C₄ alkyl, or benzyl;

R^{7d} and R^{8d} are independently H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-, or heteroaryl(C₀-C₆ alkyl)-;

R^{10d} is H, R^{1de}, C₁-C₄ alkoxy substituted with 0-1 R^{21d}, N(R^{6d})₂, halogen, NO₂, CN, CF₃, CO₂R^{17d}, C(=O)R^{17d}, CONR^{17d}R^{20d}, -SO₂R^{17d}, -SO₂NR^{17d}R^{20d}, C₁-C₆ alkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C₃-C₆ alkenyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C₃-C₇ cycloalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C₄-C₁₁ cycloalkylalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, aryl substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d}, or aryl(C₁-C₆ alkyl)- substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d};

R^{10de} is H, C₁-C₄ alkoxy substituted with 0-1 R^{21d}, N(R^{6d})₂, halogen, NO₂, CN, CF₃, CO₂R^{17d}, C(=O)R^{17d}, CONR^{17d}R^{20d}, -SO₂R^{17d}, -SO₂NR^{17d}R^{20d}, C₁-C₆ alkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C₃-C₆ alkenyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C₃-C₇ cycloalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C₄-C₁₁ cycloalkylalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, aryl substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d}, or aryl(C₁-C₆ alkyl)- substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d};

R^{11d} is H, halogen, CF₃, CN, NO₂, hydroxy, NR^{2d}R^{3d}, C₁-C₄ alkyl substituted with 0-1 R^{21d}, C₁-C₄ alkoxy substituted with 0-1 R^{21d}, aryl substituted with 0-1 R^{21d}, aryl(C₁-C₆ alkyl)- substituted with 0-1 R^{21d}, (C₁-C₄ alkoxy)carbonyl substituted with 0-1 R^{21d}, (C₁-C₄ alkyl)carbonyl substituted with 0-1 R^{21d},

C₁-C₄ alkylsulfonyl substituted with 0-1 R^{21d}, or C₁-C₄ alkylaminosulfonyl substituted with 0-1 R^{21d};


W^d is:

-(C(R^{12d})₂)_q^dC(=O)N(R^{13d})-, or

-C(=O)-N(R^{13d})-(C(R^{12d})₂)_q^d-;

X^d is -C(R^{12d})(R^{14d})-C(R^{12d})(R^{15d})-; or

alternatively, W^d and X^d can be taken together to be



R^{12d} is H, halogen, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇ cycloalkyl, C₄-C₁₀ cycloalkylalkyl, (C₁-C₄ alkyl)carbonyl, aryl, or aryl(C₁-C₆ alkyl)-;

R^{13d} is H, C₁-C₆ alkyl, C₃-C₇ cycloalkylmethyl, or aryl(C₁-C₆ alkyl)-;

R^{14d} is:


H, C₁-C₆ alkylthio(C₁-C₆ alkyl)-, aryl(C₁-C₁₀ alkylthioalkyl)-, aryl(C₁-C₁₀ alkoxyalkyl)-, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxyalkyl, C₁-C₆ hydroxyalkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cycloalkylalkyl, aryl(C₁-C₆ alkyl)-, heteroaryl(C₁-C₆ alkyl)-, aryl, heteroaryl, CO₂R^{17d}, C(=O)R^{17d}, or CONR^{17d}R^{20d}, provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 1 R^{16d} or 1-2 R^{11d};

R^{15d} is:

H, R^{16d}, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxyalkyl, C₁-C₁₀ alkylaminoalkyl, C₁-C₁₀ dialkylaminoalkyl, (C₁-C₁₀ alkyl)carbonyl, aryl(C₁-C₆ alkyl)carbonyl, C₁-C₁₀ alkenyl, C₁-C₁₀ alkynyl, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cycloalkylalkyl, aryl(C₁-C₆ alkyl)-, heteroaryl(C₁-C₆ alkyl)-, aryl, heteroaryl, CO₂R^{17d}, C(=O)R^{17d}, CONR^{17d}R^{20d}, SO₂R^{17d}, or SO₂NR^{17d}R^{20d}, provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may be unsubstituted or substituted independently with 1-2 R^{11d};

Y^d is:

-COR^{19d}, -SO₃H, -PO₃H, tetrazolyl, -CONHNHSO₂CF₃, -CONHSO₂R^{17d}, -CONHSO₂NHR^{17d}, -NHCOCF₃, -NHCONHSO₂R^{17d}, -NHSO₂R^{17d}, -OPO₃H₂, -OSO₃H, -PO₃H₂, -SO₃H, -SO₂NHCOR^{17d}, -SO₂NHCO₂R^{17d},



R^{16d} is:

-N(R^{20d})-C(=O)-O-R^{17d},
-N(R^{20d})-C(=O)-R^{17d},
-N(R^{20d})-C(=O)-NH-R^{17d},
-N(R^{20d})SO₂-R^{17d}, or
-N(R^{20d})SO₂-NR^{20d}R^{17d};

R^{17d} is:

C₁-C₁₀ alkyl optionally substituted with a bond to L_n, C₃-C₁₁ cycloalkyl optionally substituted with a bond to L_n, aryl(C₁-C₆ alkyl)- optionally substituted with a bond to L_n, (C₁-C₆ alkyl)aryl optionally substituted with a bond to L_n, heteroaryl(C₁-C₆ alkyl)- optionally substituted with a bond to L_n, (C₁-C₆ alkyl)heteroaryl optionally substituted with a bond to L_n, biaryl(C₁-C₆ alkyl)- optionally substituted with a bond to L_n, heteroaryl optionally substituted with a bond to L_n, aryl optionally substituted with a bond to L_n, biaryl optionally substituted with a bond to L_n, or a bond to L_n, wherein said aryl, biaryl or heteroaryl groups are also optionally substituted with 0-3 substituents selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, aryl, heteroaryl, halo, cyano, amino, CF₃, and NO₂;

R^{18d} is:

-H,
-C(=O)-O-R^{17d},
-C(=O)-R^{17d},
-C(=O)-NH-R^{17d},
-SO₂-R^{17d}, or
-SO₂-NR^{20d}R^{17d},

R^{19d} is hydroxy, C₁-C₁₀ alkyloxy, C₃-C₁₁ cycloalkyloxy, aryloxy, aryl(C₁-C₆ alkoxy)-, C₃-C₁₀ alkylcarbonyloxyalkyloxy, C₃-C₁₀ alkoxycarbonyloxyalkyloxy, C₂-C₁₀ alkoxycarbonylalkyloxy, C₅-C₁₀ cycloalkylcarbonyloxyalkyloxy, C₅-C₁₀ cycloalkoxycarbonyloxyalkyloxy, C₅-C₁₀ cycloalkoxycarbonylalkyloxy, C₇-C₁₁ aryloxycarbonylalkyloxy, C₈-C₁₂ aryloxycarbonyloxyalkyloxy, C₈-C₁₂ arylcarbonyloxyalkyloxy, C₅-C₁₀ alkoxyalkylcarbonyloxyalkyloxy,

C₅-C₁₀ (5-alkyl-1,3-dioxo-cyclopenten-2-one-yl)methyloxy, C₁₀-C₁₄ (5-aryl-1,3-dioxo-cyclopenten-2-one-yl)methyloxy, or (R^{11d})(R^{12d})N-(C₁-C₁₀ alkoxy)-;

R^{20d} is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-, or heteroaryl(C₁-C₆ alkyl)-;

R^{21d} is COOH or NR^{6d}₂;

m^d is 0-4;

n^d is 0-4;

t^d is 0-4;

p^d is 0-2;

q^d is 0-2;

r^d is 0-2;

d is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and


d' is 1-100

with the following provisos:

(1) t^d, n^d, m^d and q^d are chosen such that the number of atoms connecting R^{1d} and Y^d is in the range of 10-14; and

(2) n^d and m^d are chosen such that the value of n^d plus m^d is greater than one unless U^d is -(CH₂)_t^dQ^d(CH₂)_m^d-;

L_n is a linking group having the formula:



W is independently selected at each occurrence from the group consisting of O, S, NH, NHC(=O), C(=O)NH, NR⁸C(=O), C(=O)N R⁸, C(=O), C(=O)O, OC(=O), NHC(=S)NH, NHC(=O)NH, SO₂, SO₂NH, (OCH₂CH₂)_s, (CH₂CH₂O)_{s'}, (OCH₂CH₂CH₂)_{s"}, (CH₂CH₂CH₂O)_t, and (aa)_{t'};

aa is independently at each occurrence an amino acid;

Z is aryl substituted with 0-3 R¹⁰, C₃₋₁₀ cycloalkyl substituted with 0-3 R¹⁰, or a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from the group consisting of N, S, and O and substituted with 0-3 R¹⁰;

R⁶, R^{6a}, R⁷, R^{7a}, and R⁸ are independently selected at each occurrence from the group consisting of H, =O, COOH, SO₃H, PO₃H, C₁₋₅ alkyl substituted with 0-3 R¹⁰, aryl substituted with 0-3 R¹⁰, benzyl substituted with 0-3 R¹⁰, C₁₋₅ alkoxy substituted with 0-3 R¹⁰, NHC(=O)R¹¹, C(=O)NHR¹¹, NHC(=O)NHR¹¹, NHR¹¹, R¹¹, and a bond to C_h;

R¹⁰ is independently selected at each occurrence from the group consisting of a bond to C_h, COOR¹¹, C(=O)NHR¹¹, NHC(=O)R¹¹, OH, NHR¹¹, SO₃H, PO₃H, -OPO₃H₂, -OSO₃H, aryl substituted with 0-3 R¹¹, C₁₋₅ alkyl substituted with 0-1 R¹², C₁₋₅ alkoxy substituted with 0-1 R¹², and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from the group consisting of N, S, and O and substituted with 0-3 R¹¹;

R¹¹ is independently selected at each occurrence from the group consisting of H, alkyl substituted with 0-1 R¹², aryl substituted with 0-1 R¹², a 5-10 membered

heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-1 R¹², C₃₋₁₀ cycloalkyl substituted with 0-1 R¹², polyalkylene glycol substituted with 0-1 R¹², carbohydrate substituted with 0-1 R¹², cyclodextrin substituted with 0-1 R¹², amino acid substituted with 0-1 R¹², polycarboxyalkyl substituted with 0-1 R¹², polyazaalkyl substituted with 0-1 R¹², peptide substituted with 0-1 R¹², wherein the peptide is comprised of 2-10 amino acids, 3,6-O-disulfo-B-D-galactopyranosyl, bis(phosphonomethyl)glycine, and a bond to C_h;

R¹² is a bond to C_h;

k is 0, 1, or 2;

h is 0, 1, or 2;

h' is 0, 1, or 2;

g is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

g' is m 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

s' is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

s'' is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;



t is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;


t' is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

x is 0, 1, 2, 3, 4, or 5;

x' is 0, 1, 2, 3, 4, or 5;

C_h is a metal bonding unit having a formula selected from the group consisting of:





A^1 , A^2 , A^3 , A^4 , A^5 , A^6 , A^7 , and A^8 are independently selected at each occurrence from the group consisting of NR^{13} , $NR^{13}R^{14}$, S, SH, S(Pg), O, OH, PR^{13} , $PR^{13}R^{14}$, $P(O)R^{15}R^{16}$, and a bond to L_n ;

E is a bond, CH, or a spacer group independently selected at each occurrence from the group consisting of C_1 - C_{10} alkyl substituted with 0-3 R^{17} , aryl substituted with 0-3 R^{17} , C_3 - C_{10} cycloalkyl substituted with 0-3 R^{17} , heterocyclo- C_1 - C_{10} alkyl substituted with 0-3 R^{17} , wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O, C_6 - C_{10} aryl- C_1 - C_{10} alkyl substituted with 0-3 R^{17} , C_1 - C_{10} alkyl- C_6 - C_{10} aryl- substituted with 0-3 R^{17} , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from the group consisting of N, S, and O and substituted with 0-3 R^{17} ;

R^{13} and R^{14} are each independently selected from the group consisting of a bond to L_n , hydrogen, C_1 - C_{10} alkyl substituted with 0-3 R^{17} , aryl substituted with 0-3 R^{17} , C_1 - C_{10} cycloalkyl substituted with 0-3 R^{17} , heterocyclo- C_1 - C_{10} alkyl substituted with

0-3 R¹⁷, wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from consisting of N, S, and O, C₆₋₁₀ aryl-C₁₋₁₀ alkyl substituted with 0-3 R¹⁷, C₁₋₁₀ alkyl-C₆₋₁₀ aryl- substituted with 0-3 R¹⁷, a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-3 R¹⁷, and an electron, provided that when one of R¹³ or R¹⁴ is an electron, then the other is also an electron;

alternatively, R¹³ and R¹⁴ combine to form =C(R²⁰)(R²¹);

R¹⁵ and R¹⁶ are each independently selected from the group consisting of a bond to L_n, -OH, C_{1-C10} alkyl substituted with 0-3 R¹⁷, C_{1-C10} alkyl substituted with 0-3 R¹⁷, aryl substituted with 0-3 R¹⁷, C₃₋₁₀ cycloalkyl substituted with 0-3 R¹⁷, heterocyclo-C₁₋₁₀ alkyl substituted with 0-3 R¹⁷, wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O, C₆₋₁₀ aryl-C₁₋₁₀ alkyl substituted with 0-3 R¹⁷, C₁₋₁₀ alkyl-C₆₋₁₀ aryl- substituted with 0-3 R¹⁷, and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from the group consisting of N, S, and O and substituted with 0-3 R¹⁷;

R¹⁷ is independently selected at each occurrence from the group consisting of a bond to L_n, =O, F, Cl, Br, I, -CF₃, -CN, -CO₂R¹⁸, -C(=O)R¹⁸, -C(=O)N(R¹⁸)₂, -CHO, -CH₂OR¹⁸, -OC(=O)R¹⁸, -OC(=O)OR^{18a}, -OR¹⁸, -OC(=O)N(R¹⁸)₂, -NR¹⁹C(=O)R¹⁸, -NR¹⁹C(=O)OR^{18a}, -NR¹⁹C(=O)N(R¹⁸)₂, -NR¹⁹SO₂N(R¹⁸)₂, -NR¹⁹SO₂R^{18a}, -SO₃H, -SO₂R^{18a}, -SR¹⁸, -S(=O)R^{18a}, -SO₂N(R¹⁸)₂, -N(R¹⁸)₂, -NHC(=S)NHR¹⁸, =NOR¹⁸, NO₂, -C(=O)NHOR¹⁸, -C(=O)NHN(R¹⁸)R^{18a},


-OCH₂CO₂H, 2-(1-morpholino)ethoxy, C₁-C₅ alkyl, C₂-C₄ alkenyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkylmethyl, C₂-C₆ alkoxyalkyl, aryl substituted with 0-2 R¹⁸, and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from the group consisting of N, S, and O;

R¹⁸, R^{18a}, and R¹⁹ are independently selected at each occurrence from the group consisting of a bond to L_n, H, C₁-C₆ alkyl, phenyl, benzyl, C₁-C₆ alkoxy, halide, nitro, cyano, and trifluoromethyl;

Pg is a thiol protecting group;

R²⁰ and R²¹ are independently selected from the group consisting of H, C₁-C₁₀ alkyl, -CN, -CO₂R²⁵, -C(=O)R²⁵, -C(=O)N(R²⁵)₂, C₂-C₁₀ 1-alkene substituted with 0-3 R²³, C₂-C₁₀ 1-alkyne substituted with 0-3 R²³, aryl substituted with 0-3 R²³, unsaturated 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from the group consisting of N, S, and O and substituted with 0-3 R²³, and unsaturated C₃-10 carbocycle substituted with 0-3 R²³;

alternatively, R²⁰ and R²¹, taken together with the divalent carbon radical to which they are attached form:



R²² and R²³ are independently selected from the group consisting of H, R²⁴, C₁-C₁₀ alkyl substituted with 0-3 R²⁴, C₂-C₁₀ alkenyl substituted with 0-3 R²⁴, C₂-C₁₀ alkynyl substituted with 0-3 R²⁴, aryl substituted with 0-3 R²⁴, a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from the group consisting of N, S, and O and substituted with 0-3 R²⁴, and C₃-10 carbocycle substituted with 0-3 R²⁴;

alternatively, R²², R²³ taken together form a fused aromatic or a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from the group consisting of N, S, and O;








a and **b** indicate the positions of optional double bonds and **n** is 0 or 1;

R²⁴ is independently selected at each occurrence from the group consisting of =O, F, Cl, Br, I, -CF₃, -CN, -CO₂R²⁵, -C(=O)R²⁵, -C(=O)N(R²⁵)₂, -N(R²⁵)₃⁺, -CH₂OR²⁵, -OC(=O)R²⁵, -OC(=O)OR^{25a}, -OR²⁵, -OC(=O)N(R²⁵)₂, -NR²⁶C(=O)R²⁵, -NR²⁶C(=O)OR^{25a}, -NR²⁶C(=O)N(R²⁵)₂, -NR²⁶SO₂N(R²⁵)₂, -NR²⁶SO₂R^{25a}, -SO₃H, -SO₂R^{25a}, -SR²⁵, -S(=O)R^{25a}, -SO₂N(R²⁵)₂, -N(R²⁵)₂, =NOR²⁵, -C(=O)NHOR²⁵, -OCH₂CO₂H, and 2-(1-morpholino)ethoxy; and,

R²⁵, R^{25a}, and R²⁶ are each independently selected at each occurrence from the group consisting of hydrogen and C₁-C₆ alkyl.

59. (New) A compound according to Claim 58, wherein:

R^{1de} is:



A^d and B^d are independently -CH₂-, -O-, -N(R^{2d})-, or -C(=O)-;

A^{1d} and B^{1d} are independently -CH₂- or -N(R^{3d})-;

D^d is $-N(R^{2d})-$, $-O-$, $-S-$, $-C(=O)-$ or $-SO_2-$;

E^d-F^d is $-C(R^{4d})=C(R^{5d})-$, $-N=C(R^{4d})-$, $-C(R^{4d})=N-$, or $-C(R^{4d})_2C(R^{5d})_2-$;

J^d , K^d , L^d and M^d are independently $C(R^{4d})-$, $-C(R^{5d})-$ or $-N-$, provided that at least one of J^d , K^d , L^d and M^d is not $-N-$;

R^{2d} is H, C₁-C₆ alkyl, (C₁-C₆ alkyl)carbonyl, (C₁-C₆ alkoxy)carbonyl, C₁-C₆ alkylaminocarbonyl, C₃-C₆ alkenyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, heteroaryl(C₁-C₆ alkyl)carbonyl, heteroarylcarbonyl, aryl(C₁-C₆ alkyl)-, (C₁-C₆ alkyl)carbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, aryl(C₁-C₆ alkyl)sulfonyl, heteroarylsulfonyl, heteroaryl(C₁-C₆ alkyl)sulfonyl, aryloxycarbonyl, or aryl(C₁-C₆ alkoxy)carbonyl, wherein said aryl groups are substituted with 0-2 substituents selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, halo, CF₃, and nitro;

R^{3d} is H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-, or heteroaryl(C₁-C₆ alkyl)-;

R^{4d} and R^{5d} are independently H, C₁-C₄ alkoxy, $NR^{2d}R^{3d}$, halogen, NO₂, CN, CF₃, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-, C₂-C₇ alkylcarbonyl, or arylcarbonyl;

alternatively, when substituents on adjacent atoms, R^{4d} and R^{5d} can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-

7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, halo, cyano, amino, CF₃, or NO₂;

U^d is:

-(CH₂)_n^d-,

-(CH₂)_n^d(CR^{7d}=CR^{8d})(CH₂)_m^d-,

-(CH₂)_t^dQ^d(CH₂)_m^d-,

-(CH₂)_n^dO(CH₂)_m^d-,

-(CH₂)_n^dN(R^{6d})(CH₂)_m^d-,

-(CH₂)_n^dC(=O)(CH₂)_m^d-, or

-(CH₂)_n^dS(O)_p^d(CH₂)_m^d-;

wherein one or more of the methylene groups in U^d is optionally substituted with R^{7d};

Q^d is 1,2-phenylene, 1,3-phenylene, 2,3-pyridinylene, 3,4-pyridinylene, or 2,4-pyridinylene;


R^{6d} is H, C₁-C₄ alkyl, or benzyl;

R^{7d} and R^{8d} are independently H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-, or heteroaryl(C₀-C₆ alkyl)-;

W^d is -C(=O)-N(R^{13d})-(C(R^{12d})₂)_q^d-;

X^d is $-C(R^{12d})(R^{14d})-C(R^{12d})(R^{15d})-$;


alternatively, W^d and X^d can be taken together to be



R^{12d} is H or C_1 - C_6 alkyl;

Y^d is:

$-COR^{19d}$, $-SO_3H$,



d is 1, 2, 3, 4, or 5;

d' is 1-50;

W is independently selected at each occurrence from the group consisting of O, NH,

$NHC(=O)$, $C(=O)NH$, $NR^8C(=O)$, $C(=O)NR^8$, $C(=O)$, $C(=O)O$, $OC(=O)$,

$NHC(=S)NH$, $NHC(=O)NH$, SO_2 , $(OCH_2CH_2)_s$, $(CH_2CH_2O)_s$, $(OCH_2CH_2CH_2)_s$,

$(CH_2CH_2CH_2O)_t$, and $(aa)_t$;

aa is independently at each occurrence an amino acid;

Z is aryl substituted with 0-1 R¹⁰, C₃₋₁₀ cycloalkyl substituted with 0-1 R¹⁰, or a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from the group consisting of N, S, and O and substituted with 0-1 R¹⁰;

R⁶, R^{6a}, R⁷, R^{7a}, and R⁸ are independently selected at each occurrence from the group consisting of H, =O, COOH, SO₃H, C₁₋₅ alkyl substituted with 0-1 R¹⁰, aryl substituted with 0-1 R¹⁰, benzyl substituted with 0-1 R¹⁰, and C₁₋₅ alkoxy substituted with 0-1 R¹⁰, NHC(=O)R¹¹, C(=O)NHR¹¹, NHC(=O)NHR¹¹, NHR¹¹, R¹¹, and a bond to C_H;

k is 0 or 1;

s is 0, 1, 2, 3, 4, or 5;

s' is 0, 1, 2, 3, 4, or 5;

s'' is 0, 1, 2, 3, 4, or 5;

t is s 0, 1, 2, 3, 4, or 5;

A¹, A², A³, A⁴, A⁵, A⁶, A⁷, and A⁸ are independently selected at each occurrence from the group consisting of NR¹³, NR¹³R¹⁴, S, SH, S(Pg), OH, and a bond to L_n;

E is a bond, CH, or a spacer group independently selected at each occurrence from the group consisting of C₁₋₁₀ alkyl substituted with 0-3 R¹⁷, aryl substituted with 0-3 R¹⁷, C₃₋₁₀ cycloalkyl substituted with 0-3 R¹⁷, and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from the group consisting of N, S, and O and substituted with 0-3 R¹⁷;

R¹³ and R¹⁴ are each independently selected from the group consisting of a bond to L_n, hydrogen, C₁-C₁₀ alkyl substituted with 0-3 R¹⁷, aryl substituted with 0-3 R¹⁷, a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from the group consisting of N, S, and O and substituted with 0-3 R¹⁷, and an electron, provided that when one of R¹³ or R¹⁴ is an electron, then the other is also an electron;


alternatively, R¹³ and R¹⁴ combine to form =C(R²⁰)(R²¹);

R¹⁷ is independently selected at each occurrence from the group consisting of a bond to L_n, =O, F, Cl, Br, I, -CF₃, -CN, -CO₂R¹⁸, -C(=O)R¹⁸, -C(=O)N(R¹⁸)₂, -CH₂OR¹⁸, -OC(=O)R¹⁸, -OC(=O)OR^{18a}, -OR¹⁸, -OC(=O)N(R¹⁸)₂, -NR¹⁹C(=O)R¹⁸, -NR¹⁹C(=O)OR^{18a}, -NR¹⁹C(=O)N(R¹⁸)₂, -NR¹⁹SO₂N(R¹⁸)₂, -NR¹⁹SO₂R^{18a}, -SO₃H, -SO₂R^{18a}, -S(=O)R^{18a}, -SO₂N(R¹⁸)₂, -N(R¹⁸)₂, -NHC(=S)NHR¹⁸, =NOR¹⁸, -C(=O)NHN(R¹⁸)R^{18a}, -OCH₂CO₂H, and 2-(1-morpholino)ethoxy;

R¹⁸, R^{18a}, and R¹⁹ are independently selected at each occurrence from the group consisting of a bond to L_n, H, and C₁-C₆ alkyl;

R²⁰ and R²¹ are independently selected from the group consisting of H, C₁-C₅ alkyl, -CO₂R²⁵, C₂-C₅ 1-alkene substituted with 0-3 R²³, C₂-C₅ 1-alkyne substituted with 0-3 R²³, aryl substituted with 0-3 R²³, and unsaturated 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from the group consisting of N, S, and O and substituted with 0-3 R²³;

alternatively, R^{20} and R^{21} , taken together with the divalent carbon radical to which they are attached form:



R^{22} and R^{23} are independently H or R^{24} ;


alternatively, R^{22} , R^{23} taken together form a fused aromatic or a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from the group consisting of N, S, and O;


R^{24} is independently selected at each occurrence from the group consisting of $-\text{CO}_2R^{25}$, $-\text{C}(=\text{O})\text{N}(R^{25})_2$, $-\text{CH}_2\text{OR}^{25}$, $-\text{OC}(=\text{O})R^{25}$, $-\text{OR}^{25}$, $-\text{SO}_3\text{H}$, $-\text{N}(R^{25})_2$, and $-\text{OCH}_2\text{CO}_2\text{H}$; and,

R^{25} is independently selected at each occurrence from the group the group consisting of H and $\text{C}_1\text{-C}_3$ alkyl.

60. (New) A compound according to Claim 59, wherein:

R^{1de} is:





wherein the above heterocycles are optionally substituted with 0-2 substituents selected from the group consisting of NH₂, halogen, NO₂, CN, CF₃, C₁-C₄ alkoxy, C₁-C₆ alkyl, and C₃-C₇ cycloalkyl;

U^d is -(CH₂)_n-, -(CH₂)_t Q^d (CH₂)_m - or -C(=O)(CH₂)_n -₁-, wherein one of the methylene groups is optionally substituted with R^{7d};

R^{7d} is C₁-C₆ alkyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl), heteroaryl, or heteroaryl(C₁-C₆ alkyl);

R^{10d} is H, R^{1de}, C₁-C₄ alkoxy substituted with 0-1 R^{21d}, halogen, CO₂R^{17d}, CONR^{17d}R^{20d}, C₁-C₆ alkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C₃-C₇ cycloalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C₄-C₁₁ cycloalkylalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, or aryl(C₁-C₆ alkyl)- substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d};

R^{10de} is H, C₁-C₄ alkoxy substituted with 0-1 R^{21d}, halogen, CO₂R^{17d}, CONR^{17d}R^{20d}, C₁-C₆ alkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C₃-C₇ cycloalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, C₄-C₁₁ cycloalkylalkyl substituted with 0-1 R^{15d} or 0-1 R^{21d}, or aryl(C₁-C₆ alkyl)- substituted with 0-1 R^{15d} or 0-2 R^{11d} or 0-1 R^{21d};

DOCKET NO.: DM-6999 (BMS-2594)
Application No.: 10/770,380
Office Action Dated: June 16, 2006

PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116

W^d is $-C(=O)-N(R^{13d})-$;

X^d is $-CH(R^{14d})-CH(R^{15d})-$;

R^{13d} is H or CH_3 ;

R^{14d} is:

H, C_1 - C_{10} alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents selected from the group consisting of C_1 - C_4 alkyl, C_1 - C_4 alkoxy, aryl, halo, cyano, amino, CF_3 , and NO_2 ;

R^{15d} is H or R^{16d} ;

Y^d is $-COR^{19d}$;

R^{19d} is:

hydroxy, C_1 - C_{10} alkoxy,
methylcarbonyloxymethoxy-,
ethylcarbonyloxymethoxy-,
t-butylcarbonyloxymethoxy-,
cyclohexylcarbonyloxymethoxy-,
1-(methylcarbonyloxy)ethoxy-,
1-(ethylcarbonyloxy)ethoxy-,
1-(*t*-butylcarbonyloxy)ethoxy-,
1-(cyclohexylcarbonyloxy)ethoxy-,
i-propyloxy carbonyloxymethoxy-,
t-butyloxy carbonyloxymethoxy-,

DOCKET NO.: DM-6999 (BMS-2594)
Application No.: 10/770,380
Office Action Dated: June 16, 2006

PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116

1-(i-propyloxycarbonyloxy)ethoxy-,
1-(cyclohexyloxycarbonyloxy)ethoxy-,
1-(*t*-butyloxycarbonyloxy)ethoxy-,
dimethylaminoethoxy-,
diethylaminoethoxy-,
(5-methyl-1,3-dioxacyclopenten-2-on-4-yl)methoxy-,
(5-(*t*-butyl)-1,3-dioxacyclopenten-2-on-4-yl)methoxy-,
(1,3-dioxa-5-phenyl-cyclopenten-2-on-4-yl)methoxy-, or
1-(2-(2-methoxypropyl)carbonyloxy)ethoxy-;


R^{20d} is H or CH₃;

m^d is 0 or 1;

n^d is 1-4;

t^d is 0 or 1;

C_h is



A¹ is OH, or a bond to L_n;

A², A⁴, and A⁶ are each N;

DOCKET NO.: DM-6999 (BMS-2594)
Application No.: 10/770,380
Office Action Dated: June 16, 2006

**PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116**


A³, A⁵, and A⁸ are each OH;

A⁷ is a bond to L_n or NH-bond to L_n;

E is a C₂ alkyl substituted with 0-1 R¹⁷;

R¹⁷ is =O;

alternatively, C_h is



A¹ is OH or a bond to L_n;

A², A³ and A⁴ are each N;

A⁵, A⁶ and A⁸ are each OH;


A⁷ is a bond to L_n;

DOCKET NO.: DM-6999 (BMS-2594)
Application No.: 10/770,380
Office Action Dated: June 16, 2006

**PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116**

E is a C₂ alkyl substituted with 0-1 R¹⁷;

R¹⁷ is =O;

alternatively, C_h is  ;

A¹ is NH₂ or N=C(R²⁰)(R²¹);

E is a bond;

A² is NHR¹³;

R¹³ is a heterocycle substituted with R¹⁷, the heterocycle being selected from pyridine and pyrimidine;

R¹⁷ is a bond to L_n, C(=O)NHR¹⁸ or C(=O)R¹⁸;


R¹⁸ is a bond to L_n;

R²⁴ is -CO₂R²⁵, -OR²⁵, -SO₃H, or -N(R²⁵)₂; and,

R²⁵ is independently selected at each occurrence from the group consisting of hydrogen and methyl.

61. (New) A compound according to Claim 60, wherein:

R^{1de} is



wherein the above heterocycles are optionally substituted with 0-2 substituents selected from the group consisting of NH₂, halogen, NO₂, CN, CF₃, C₁-C₄ alkoxy, C₁-C₆ alkyl, and C₃-C₇ cycloalkyl.

62. (New) A compound according to Claim 59, wherein the compound is:

2-(((4-(4-(((3-(2-(2-(3-((6-((1-aza-2-(2-sulfophenyl)vinyl)amino)(3-pyridyl))carbonylamino)propoxy)ethoxy)ethoxy)propyl)amino)sulfonyl)-phenyl)phenyl)sulfonyl)amino)-3-((1-(3-(imidazole-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)propanoic acid;

2-(2-aza-2-((5-(N-(1,3-bis(3-(2-(2-(3-(((4-(4-(((1-carboxy-2-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)ethyl)amino)sulfonyl)-phenyl)phenyl)sulfonyl)amino)propoxy)ethoxy)ethoxy)propyl)carbamoyl)propyl)-carbamoyl)(2-pyridyl))amino)vinyl)benzenesulfonic acid;

2-((6-((1-aza-2-(sulfophenyl)vinyl)amino)(3-pyridyl))carbonylamino)-4-(N-(3-(2-(2-(3-(((4-(4-(((1-carboxy-2-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))-carbonylamino)ethyl)amino)sulfonyl)phenyl)phenyl)sulfonyl)amino)propoxy)-ethoxy)ethoxy)propyl)carbamoyl)butanoic acid;

3-((1-(3-(imidazole-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)-2-(((4-(4-(((3-(2-(2-(3-(2-(1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)cyclododecyl)-acetyl)amino)propoxy)ethoxy)ethoxy)propyl)amino)sulfonyl)-phenyl)phenyl)sulfonyl)amino)propanoic acid;

2-(6-((6-((1-aza-2-(2-sulfophenyl)vinyl)-amino)(3-pyridyl))carbonylamino)hexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)-propanoic acid;


2-(((6-((1-aza-2-(2-sulfophenyl)vinyl)-amino)(3-pyridyl))carbonylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)propanoic acid;

[2-[[[5-[carbonyl]-2-pyridinyl]hydrazono]methyl]-benzenesulfonic acid]-Glu(2-(6-aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid)(2-(6-aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid);

[2-[[[5-[carbonyl]-2-pyridinyl]hydrazono]methyl]-benzenesulfonic acid]-Glu-bis-[Glu(2-(6-Aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid)(2-(6-aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid)];

2-(1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)-1-cyclododecyl)acetyl- {2-(6-aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid};


2-(1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)-1-cyclododecyl)acetyl-Glu {2-(6-Aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid} {2-(6-Aminohexanoylamino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonyl-amino)propanoic acid};



;




Office Action Dated: June 16, 2006

**PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116**



DOCKET NO.: DM-6999 (BMS-2594)
 Application No.: 10/770,380
 Office Action Dated: June 16, 2006



PATENT
 REPLY FILED UNDER EXPEDITED
 PROCEDURE PURSUANT TO
 37 CFR § 1.116




2-(((4-(3-(N-(3-(2-(2-(3-(2-(1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)cyclododecylacetyl-amino)-6-amino-hexanoylamino)propoxy)ethoxy)ethoxy)propyl)carbamo-yl)propoxy)-2,6-dimethylphenyl)sulfonyl)amino)-3-((1-(3-(imidazol-2-ylamino)propyl)(1H-indazol-5-yl))carbonylamino)propionic acid salt;

DOCKET NO.: DM-6999 (BMS-2594)
 Application No.: 10/770,380
 Office Action Dated: June 16, 2006

PATENT
 REPLY FILED UNDER EXPEDITED
 PROCEDURE PURSUANT TO
 37 CFR § 1.116



2-([4-(3-{N-[2-((2R)-3-Sulfo-2-{2-[1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)cyclododecyl]acetyl amino} propyl) ethyl] carbamoyl} propoxy)-2,6-dimethyl phenyl] sulfonyl} amino)(2S)-3-({1-[3-(imidazol-2-yl amino) propyl](1H-indazol-5-yl)} carbonyl amino) propanoic Acid;



2-[(4-[4-([2-((2R)-3-Sulfo-2-{2-[1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)cyclododecyl]-acetylamino}propyl)ethyl]amino}sulfonyl)phenyl]phenyl)sulfonyl]amino](2S)-3-([3-(imidazol-2-ylamino)propyl](1H-indazol-5-yl))carbonylamino]propanoic Acid;

(4S)-4-(N-{1-[N-(2-{4-[4-([(1S)-1-carboxy-2-({1-[3-(2-pyridylamino)propyl](1H-indazol-5-yl))carbonylamino]ethyl]amino}sulfonyl)-3,5-dimethylphenoxy]butanoylamino}ethyl)carbamoyl]-3-carboxypropyl}carbamoyl)-4-{2-[1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)cyclododecyl]acetylamino}butanoic acid;

(4S)-4-(N-{1-[N-(2-{4-[4-([(1S)-1-carboxy-2-({1-[3-(imidazol-2-ylamino)propyl](1H-indazol-5-yl))carbonylamino]ethyl]amino}sulfonyl)-3,5-dimethylphenoxy]butanoylamino}ethyl)carbamoyl]-3-carboxypropyl}carbamoyl)-4-{2-[1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)cyclododecyl]acetylamino}butanoic acid;

(4S)-4-{N-[(1S)-1-(N-{1,3-bis[N-(2-{4-[4-([(1S)-1-carboxy-2-({1-[3-(imidazol-2-ylamino)propyl](1H-indazol-5-yl))carbonylamino]ethyl]amino}sulfonyl)-3,5-

dimethylphenoxy]butanoylamino} ethyl) carbamoyl] propyl} carbamoyl)-3-carboxypropyl] carbamoyl}-4-(6-{2-[1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)cyclododecyl]acetyl amino} hexanoylamino)butanoic acid;

(4S)-4-(N-{1-[N-(2-{4-[4-({[(1S)-1-carboxy-2-(1-[3-(3,4,5,6-tetrahydropyrimidin-2-ylamino)propyl](1H-indazol-5-yl)} carbonylamino)ethyl]amino} sulfonyl)-3,5-dimethylphenoxy]butanoylamino} ethyl) carbamoyl]-3-carboxy propyl} carbamoyl)-4-{2-[1,4,7,10-tetraaza-4,7,10-tris (carboxymethyl)cyclododecyl]acetyl amino} butanoic acid;

(4S)-4-(N-{1-[N-(2-{4-[4-({[(1S)-1-carboxy-2-(1-methyl-3-[3-(2-3,4,5,6-tetrahydropyridylamino)propyl] (1H-indazol-6-yl)} carbonylamino)ethyl]amino} sulfonyl)-3,5-dimethylphenoxy]butanoylamino} ethyl) carbamoyl]-3-carboxypropyl} carbamoyl)-4-{2-[1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)cyclododecyl]acetyl amino} butanoic acid;

(4S)-4-(N-{(1S)-1-[N-(2-{4-[4-({[(1S)-1-carboxy-2-(1-[2-(2-3,4,5,6-tetrahydropyridylamino)ethyl] (1H-indazol-5-yl)} carbonylamino)ethyl]amino} sulfonyl)-3,5-dimethylphenoxy]butanoylamino} ethyl) carbamoyl]-3-carboxy propyl} carbamoyl)-4-{2-[1,4,7,10-tetraaza-4,7,10-tris (carboxymethyl)cyclododecyl]acetyl amino} butanoic acid;

(2S)-2-{{(2,6-dimethyl-4-{3-[N-(2-{2-[1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)cyclododecyl]acetyl amino} ethyl) carbamoyl]propoxy} phenyl)sulfonyl]amino}-3-({2-[2-(2-3,4,5,6-tetrahydropyridylamino)ethyl](2-hydro-1H-indazol-5-yl)} carbonylamino)propanoic acid;

(4S)-4-{N-[(1S)-1-(N-{2-[(4-[4-([(1S)-1-carboxy-2-(1-[2-(2-3,4,5,6-tetrahydropyridylamino)ethyl] (1H-indazol-5-yl)) carbonylamino)ethyl]amino} sulfonyl)phenyl]phenyl} sulfonyl)amino]ethyl} carbamoyl)-3-carboxypropyl] carbamoyl}-4-{2-[1,4,7,10-tetraaza-4,7,10-tris(carboxy-methyl)cyclododecyl]acetyl amino} butanoic acid;

(4S)-4-{N-[(1S)-1-(N-{2-[(4-[4-([(1S)-1-carboxy-2-(1-[3-(3,4,5,6-tetrahydropyrimidin-2-ylamino) propyl](1H-indazol-5-yl)) carbonylamino)ethyl]amino} sulfonyl)phenyl]phenyl} sulfonyl)amino]ethyl} carbamoyl)-3-carboxy propyl] carbamoyl}-4-{2-[1,4,7,10-tetraaza-4,7,10-tris (carboxymethyl)cyclododecyl]acetyl amino} butanoic acid;

(2S)-3-({3-[(imidazol-2-ylamino) methyl]-1-methyl(1H-indazol-6-yl)} carbonylamino)-2-({[4-(4-{[(2-{2-[1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl) cyclododecyl]acetyl amino} ethyl)amino] sulfonyl} phenyl)phenyl] sulfonyl} amino)prop anoic acid;

3-[(7-{3-[(6-{[(1E)-1-aza-2-(2-sulfo phenyl)vinyl] amino} (3-pyridyl)) carbonylamino] propoxy}-1-[3-(imidazol-2-ylamino) propyl](1H-indazol-5-yl))-carbonylamino](2S)-2-{[(2,4,6-trimethylphenyl) sulfonyl]-amino} propanoic acid;
or

3-{[1-[3-(imidazol-2-ylamino) propyl]-7-(3-{2-[1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl) cyclododecyl]-acetyl amino} propoxy)(1H-indazol-5-yl)] carbonylamino}-2-{[(2,4,6-trimethylphenyl) sulfonyl] amino} propanoic acid;

or a pharmaceutically acceptable salt form thereof.